IL13 and primary cutaneous T-cell non-Hodgkin lymphoma: Remarkably, this particular variant further exhibits a significant association with cutaneous T-cell lymphoma [116], a malignancy that has been observed to manifest in some cases of AD patients following the administration of dupilumab [117], an anti-IL4RA biological drug that inhibits both IL4 and IL13 signaling [11].